Published in Lancet on April 10, 1993
Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest (1996) 1.65
Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol (2004) 1.17
Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis (2000) 1.15
Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther (2008) 1.12
Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol (2007) 1.09
Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin Exp Immunol (1999) 1.03
Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clin Exp Immunol (2001) 0.99
Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease. Rheumatol Int (2009) 0.97
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol (2011) 0.96
Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc Med J (2011) 0.90
Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm (2014) 0.86
Food restriction and fish oil suppress atherogenic risk factors in lupus-prone (NZB x NZW) F1 mice. J Clin Immunol (2003) 0.86
Anticardiolipin antibodies and cardiovascular disease. J R Soc Med (1995) 0.86
Risk factors for development of left ventricular thrombus after first acute anterior myocardial infarction-association with anticardiolipin antibodies. Thromb J (2010) 0.83
Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol Int (2003) 0.82
Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases. Clin Immunol (2012) 0.81
Administration of M. leprae Hsp65 interferes with the murine lupus progression. PLoS One (2008) 0.81
Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus. Clin Exp Immunol (1999) 0.81
Low levels of IgM antibodies to oxidized cardiolipin increase and high levels decrease risk of cardiovascular disease among 60-year olds: a prospective study. BMC Cardiovasc Disord (2013) 0.80
The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol (2015) 0.79
Autoantibodies to malondialdehyde-modified epitope in connective tissue diseases and vasculitides. Clin Exp Immunol (1995) 0.78
Association of anticardiolipin antibodies with vascular injury: possible mechanisms. Postgrad Med J (2000) 0.78
Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity. Clin Exp Immunol (2007) 0.78
Evaluation of the hypolipidemic activity of 6,7-dimethoxycoumarin on placental tissue factor mRNA expression in experimental anti-phospholipid syndrome. Pharmacogn Mag (2013) 0.77
Prevalence of antibodies against oxidised LDL in a cohort of 163 patients with positive anti-phospholipid antibodies and recent thrombosis. Rheumatol Int (2005) 0.76
Accelerated vascular disease in systemic lupus erythematosus: role of macrophage. Clin Immunol (2015) 0.76
Update on cardiovascular disease in lupus. Curr Opin Rheumatol (2016) 0.75
Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Medicine (Baltimore) (2016) 0.75
Human IgM Antibodies to Malondialdehyde Conjugated With Albumin Are Negatively Associated With Cardiovascular Disease Among 60-Year-Olds. J Am Heart Assoc (2016) 0.75
Enhanced oxidative status but not corresponding elevated antioxidative status by anticardiolipin antibody and disease activity in patients with systemic lupus erythematosus. Rheumatol Int (2007) 0.75
Clinical significance of antibodies against oxidised low density lipoprotein in early RA. Ann Rheum Dis (1996) 0.75
Dyslipidemia and its relationship with antiphospholipid antibodies in APS patients in North Kerala. Eur J Rheumatol (2016) 0.75
[Oxidatively modified lipoproteins and their antibodies in patients with antiphospholipid syndromeand systemic lupus erythematosus]. Z Rheumatol (2004) 0.75
Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum (2000) 6.88
Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ (1980) 5.66
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet (1999) 4.98
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
HL-A 27 in reactive arthritis. A study of Yersinia arthritis and Reiter's disease. Arthritis Rheum (1974) 4.28
Arthritis associated with Yersinia enterocolitica infection. Acta Rheumatol Scand (1969) 4.03
Cardiovascular risk factor changes in Finland, 1972-1997. Int J Epidemiol (2000) 3.78
Smoking and risk of rheumatoid arthritis. J Rheumatol (1993) 3.63
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch Intern Med (1998) 3.01
Marked cross-agglutination between Brucellae and a subtype of Yersinia enterocolitica. Acta Pathol Microbiol Scand (1969) 2.57
Association of markers of systemic inflammation, C reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status. J Epidemiol Community Health (2003) 2.46
Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol (1991) 2.43
Increased incidence of alcohol-related deaths from accidents and violence in subjects with ankylosing spondylitis. Br J Rheumatol (1998) 2.28
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum (1995) 2.16
Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum (1991) 2.10
Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis (1998) 2.09
Studies of syphilitic antibodies. I. Anti-lipoidal antibodies in various stages of syphilis. Br J Vener Dis (1967) 2.07
HL-A antigen 27 and reactive arthritis. Lancet (1973) 2.07
Cardiovascular diseases in patients with rheumatoid arthritis. Scand J Rheumatol (2012) 2.03
Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol (1995) 1.96
Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum (1992) 1.90
Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol (1986) 1.88
Antifilaggrin antibodies within "normal" range predict rheumatoid arthritis in a linear fashion. J Rheumatol (2000) 1.87
Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis (1992) 1.86
Infections, inflammation, and the risk of coronary heart disease. Circulation (2000) 1.77
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Coffee consumption, rheumatoid factor, and the risk of rheumatoid arthritis. Ann Rheum Dis (2000) 1.74
Chlamydia trachomatis in acute salpingitis. Br J Vener Dis (1979) 1.69
Effects of antioxidant supplementation on platelet function: a randomized pair-matched, placebo-controlled, double-blind trial in men with low antioxidant status. Am J Clin Nutr (1991) 1.69
Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol (1995) 1.66
Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet (1982) 1.66
Serum C-reactive protein does not predict rheumatoid arthritis. J Rheumatol (2000) 1.65
Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis (2004) 1.58
Long-term effect of betaine on risk factors associated with the metabolic syndrome in healthy subjects. Eur J Clin Nutr (2010) 1.54
Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. Ann Rheum Dis (2005) 1.54
Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology (Oxford) (1999) 1.53
Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int (2001) 1.53
Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy. Clin Exp Rheumatol (1994) 1.52
Joint symptoms and diseases associated with moisture damage in a health center. Clin Rheumatol (2003) 1.51
Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease? Arch Intern Med (2001) 1.50
When does rheumatoid disease start? Arthritis Rheum (1985) 1.50
Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr (2001) 1.47
Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol (1993) 1.46
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis (1999) 1.44
Smoking, lung function, and rheumatoid factors. Ann Rheum Dis (1990) 1.43
Juvenile chronic arthritis in adult life: a study of long-term outcome in patients with juvenile chronic arthritis or adult rheumatoid arthritis. Clin Rheumatol (1999) 1.43
Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year study. Rheumatology (Oxford) (1999) 1.43
Validity of hospital discharge data in a prospective epidemiological study on stroke and myocardial infarction. Acta Med Scand (1984) 1.43
Turnip rape and oilseed rape are new potential food allergens in children with atopic dermatitis. Allergy (2006) 1.39
Anticardiolipin response in acute infections. Clin Immunol Immunopathol (1986) 1.39
Campylobacter-triggered reactive arthritis: a population-based study. Rheumatology (Oxford) (2002) 1.38
Mortality from cancer in patients with rheumatoid arthritis. Scand J Rheumatol (1995) 1.37
Multidisciplinary biopsychosocial rehabilitation for subacute low back pain in working-age adults: a systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine (Phila Pa 1976) (2001) 1.37
Multidisciplinary biopsychosocial rehabilitation for subacute low back pain among working age adults. Cochrane Database Syst Rev (2003) 1.34
Multidisciplinary biopsychosocial rehabilitation for neck and shoulder pain among working age adults. Cochrane Database Syst Rev (2003) 1.33
Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst (1990) 1.33
Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis (1994) 1.32
Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case-control analysis of prospective data. Br Med J (Clin Res Ed) (1985) 1.32
Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis (2002) 1.32
The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem (2001) 1.30
The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis (2001) 1.29
Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology (2001) 1.28
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
Rheumatoid factor, chronic arthritis and mortality. Ann Rheum Dis (1995) 1.26
Mortality in rheumatoid arthritis. Semin Arthritis Rheum (1995) 1.26
Serum antioxidants and risk of rheumatoid arthritis. Ann Rheum Dis (1994) 1.24
Shift in the incidence of rheumatoid arthritis toward elderly patients in Finland during 1975-1990. Clin Exp Rheumatol (1997) 1.24
Multidisciplinary rehabilitation for fibromyalgia and musculoskeletal pain in working age adults. Cochrane Database Syst Rev (2000) 1.23
Experimentally induced mononucleosis-like heterophile antibodies in man. Clin Exp Immunol (1969) 1.22
Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol (2004) 1.21
Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation (1995) 1.21
Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis (1996) 1.20
Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol (2000) 1.20
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol (2011) 1.19
Reactive arthritis following an outbreak of Salmonella infection in Finland. Br J Rheumatol (1994) 1.19
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis. Genes Immun (2005) 1.19
The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J (1996) 1.19
Risk factors for subarachnoid hemorrhage in a longitudinal population study. J Clin Epidemiol (1991) 1.19
Reactive arthritis. Clin Rheum Dis (1985) 1.18
Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum (1988) 1.18
Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum (1996) 1.17
Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol (1998) 1.17
Clinical, radiographic and MRI findings of the temporomandibular joint in patients with different rheumatic diseases. Int J Oral Maxillofac Surg (2006) 1.17
Production of tumour necrosis factor and interleukin 1 by monocytes of patients with previous Yersinia arthritis. Clin Exp Immunol (1988) 1.16
Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol (2000) 1.16
Human plasma lecithin-cholesterol acyltransferase. An elucidation of the catalytic mechanism. J Biol Chem (1986) 1.15